Fluid and imaging astrocyte biomarker alterations in Alzheimer’s disease

Takeaway

  • Cerebral spinal fluid (CSF) glial fibrillary acid protein (GFAP) and YKL-40 levels and S100B blood levels, are biomarkers of astrocytes found consistently altered in Alzheimer’s disease (AD).

Why this matters

    Biomarkers for AD alone do not predict advancement to symptomatic AD in cognitively unimpaired (CU) individuals, thus the inclusion of astrocyte biomarkers in clinical research has been suggested. Results from this study indicate that GFAP, YKL-40, and S100B may be worthwhile biomarkers for inclusion in AD clinical research.